- Home
- BCAR vs OVID Comparison
BCAR vs OVID Comparison
Compare BCAR & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.16
Company Overview
Basic Information| Metric | BCAR | OVID |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.6M | 365.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BCAR | OVID |
|---|---|---|
| Price | $10.13 | $2.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 225.4K | ★ 3.6M |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $9.89 | $0.24 |
| 52 Week High | $10.65 | $2.72 |
Technical Indicators
Market Signals| Indicator | BCAR | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 53.62 |
| Support Level | $10.00 | $1.31 |
| Resistance Level | $10.65 | $2.38 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 45.45 | 34.13 |
Price Performance
Historical Comparison BCAR
OVID
About BCAR D. Boral ARC Acquisition I Corp. Class A Ordinary Shares
D Boral ARC Acquisition I Corp is a blank check company.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.